Left ventricular hypertrophy (LVH), diagnosed by electrocardiography or the more accurate echocardiographic technique, is regarded as a cardinal manifestation of subclinical organ damage in a variety of settings, including general population samples, subjects with hypertension, diabetes, renal failure, and coronary artery disease. 1, 2 LVH is the result of the combined effect on cardiac structure of hemodynamic and nonhemodynamic unhealthy factors and is a powerful, integrated marker of increased cardiovascular risk. 3, 4 In particular, a growing body of evidence supports the interplay between blood pressure (BP) and/or volume overload with genetic, ethnic, humoral, and hormonal factors as major determinants of LVH. [5] [6] [7] LVH is typically characterized by cardiomyocyte hypertrophy and interstitial fibrosis due to an imbalance between stimulatory (i.e., angiotensin II, endothelin I, catecholamines, aldosterone, basic fibroblast growth factor, insulinlike growth factor) and inhibitory factors (prostaglandins, nitric oxide, natriuretic peptides) controlling myocardial texture and growth. [8] [9] [10] [11] Experimental and clinical reports show that serum uric acid (SUA), the final break-down product of dietary or endogenous purines, impairs nitric oxide generation, and endothelial function, activates smooth muscle cell proliferation and inflammatory mediators, such as tumor necrosis factor and potentially stimulates mitogen-activated protein kinases which are known to promote cardiac hypertrophy. [12] [13] [14] [15] The role of SUA as an independent risk factor for cardiovascular disease in the community as well as in conditions characterized by high prevalence of hyperuricemia such as hypertension, diabetes, obesity metabolic syndrome, and chronic kidney disease is still debated.
is independently associated to LVH in both genders, 16, 17 some others exclusively in men 18 or in women, 19 whereas other reports failed to identify SUA as an independent risk factor. 20, 21 Scanty information is available about the power of SUA in predicting incident LVH in subjects without structural cardiac disease and the ability of hyperuricemia to identify subjects at higher risk of progression to cardiac subclinical damage.
We have addressed this topic by analyzing data prospectively collected in the Pressioni Arteriose Monitorate E Loro Associazioni (PAMELA) study on a sample representative of the population of Monza (a town near to Milan, Italy); in particular, we examined the value of SUA in predicting newonset echocardiographic LVH over a 10-year follow-up.
METHODS

Baseline general data
The PAMELA Study started in 1990-1991 and was carried out in 3,200 individuals aged between 25 and 74 years, randomly selected from the residents in Monza to be representative of its population, using the criteria of the World Health Organization Monitoring Diseases (WHO-MONICA) project performed in the same geographic area. 22 Participation rate was 64%, thus data were collected in 2051 subjects. Phone interviews were used to ascertain that demographic characteristics and medical history of nonparticipants were not different from those of participants.
The methods employed in the PAMELA study have been described in detail previously. 23 After an informed consent, subjects were invited to undergo a comprehensive clinical evaluation at the out-patient clinic of the S. Gerardo University Hospital of Monza on the morning of a working day. Collected data included full medical history, blood and urine samples, physical examination, and 3 sphygmomanometric BP measurements in the sitting position. Body weight was recorded to the nearest 0.1 kg using a calibrated electronic scale with subjects wearing indoor clothing without shoes. Height was recorded to the nearest 0.5 cm using a standardized wall-mounted height board.
BP measurements
On the same day, subjects were fitted with an ambulatory BP monitoring device (Spacelabs 90207) set to obtain automated BP and heart rate oscillometric readings every 20 minutes over 24 hours (h). Subjects were asked to pursue their normal activities during the monitoring period, to hold the arm still at time of BP reading, to go to bed no later than 11.00 pm and to arise not earlier than 7.00 am. All ambulatory BP recordings were analyzed to obtain 24-h, day-time, and night-time average systolic (S)/diastolic BP and heart rate, after editing for artifacts, based on preselected criteria. 24 Each individual was given a validated semiautomatic BP measuring device (Philips, model HP 5331) for taking BP at home at 7 am and 7 pm, using the arm contralateral to the one used for ambulatory BP monitoring.
Echocardiography
Echocardiography was performed according to standardized procedures, as previously reported. 25 In brief, M-mode and 2-dimensional echo examinations were carried out with a commercially available instrument (Acuson 128 CF, Computer Sonography). End-diastolic and end-systolic LV internal diameters, interventricular septum, and posterior wall thickness were obtained off line from 2-dimensionally guided M-mode tracings recorded at 50 to 100 cm/s speed during at least 3 consecutive cardiac cycles according to the American Society of Echocardiography. 26 LVM was estimated by the corrected American Society of Echocardiography formula: 0.8 [1.04 (LVEDD + IVS + PWT) 3 ] + 0.6 (where LVEDD is left ventricular end-diastolic diameter, IVS is ventricular septal thickness, and PWT is posterior wall diastolic thickness), and indexed to height 2.7 in order to obtain LVM index. 26, 27 Intraobserver coefficient of variation was 0.6% for LVEDD, 3.1% for IVS and 3.2% for PW diastolic thickness. LVH was defined as LVM index equal to or higher than 51 g/h 2.7 in men and 47 g/h 2.7 in women. These cutoffs have been derived from sex-specific upper limits of normality (mean plus 1.96 SD) for LV mass indexed to height 2.7 in 675 healthy individuals with sustained normotension. 25 Echocardiographic tracings were collected by 2 skilled operators and read offline by a third expert cardiologist.
Follow-up
Ten years after the first visit, survivors were contacted for a second examination during which the above-mentioned measurements were obtained again. Mean time interval between baseline and follow-up assessment was 3,895 ± 222 days (median 3,927).
A total of 1,711 subjects out of 2051 participants had a readable echocardiogram at baseline. Of them, 143 died during follow-up period, 387 were unwilling to participate or impossible to trace because they had moved out of Monza and 71 had no readable echocardiograms at the end of follow-up. Thus, a total of 1,110 subjects had a second valuable echocardiogram, 960 of them having a normal LVM at baseline ( Figure 1 ).
Based on entry data, nonparticipants were older and more frequently male than participants, they had also slightly higher BP, serum cholesterol, blood glucose, and LVM index values (data not shown).
Statistical analysis
Statistical analysis was performed by SAS System (version 9.4; SAS Institute, Cary, NC). In each subject, 3 office, 2 home and BP and heart rate values collected over 24 hours were separately averaged. The analysis was carried out on subjects with normal LVM index at baseline. Values were expressed as means ± SD or as percentages. Means were compared by Student's t-test for independent samples and categorical data analyzed by chi-square test or Fisher's exact test when appropriate. The strength of linear correlation between variables was tested by Pearson's correlation coefficient.
The rate of incidence of new-onset LVH was calculated for the total population sample and for tertiles of baseline SUA.
Similarly, odds ratio (OR) of incident LVH associated to 1 mg/dl increase of SUA was calculated by logistic regression model in the total sample considering subjects with persistently normal LVM index as reference, and separately across SUA tertiles having the lowest tertile as reference. Data were adjusted for age, gender, entry office SBP, fasting blood glucose, serum creatinine, total cholesterol, body mass index (BMI), LVM index, and use of antihypertensive drugs.
RESULTS
The present analysis included 960 participants (51%, men, mean age 49 ± 13 years, BMI 25 ± 4 kg/m 2 , and SUA 4.8 ± 1.3 mg/dl) with no LVH at baseline and with measurable echocardiographic variables of interest at follow-up examination performed 10 years later. Table 1 shows baseline demographic and clinical data of subjects with (n = 258, 26.9%) and without new-onset LVH (n = 702). Compared to this second group, subjects who developed LVH were older (+11 years) and exhibited a higher entry BMI, SUA (+0.3 mg/dl), fasting blood glucose and serum cholesterol, as well as office, home and ambulatory SBP and diastolic BP. Subjects with new-onset LVH also had greater entry LVM index (+6.8 g/height 2.7 ) than those with persistently normal LV structure.
In the whole population, SUA was significantly correlated to male sex (r = 0.54, P < 0.001), BMI (r = 0.29, P < 0.001), LVM index (r = 0.26, P < 0.001), 24-h SBP (r = 0.22, P < 0.001), and age (r = 0.14, P < 0.001). Table 2 reports unadjusted and adjusted ORs for the risk of incident LVH associated with 1-unit increase in SUA. After adjustment for gender, age, serum creatinine, baseline LVM index, and 24-h SBP, the risk of LVH entailed by 1 mg/dl SUA increase turned out be highly significant (+26%, 95% CI = 1.060-1.507, P = 0.009).
As shown in Figure 2 , the incidence of new-onset LVH increased progressively from the lowest (<4.1 mg/dl) to intermediate (4.1-5.1 mg/dl) and highest baseline SUA tertile (>5.1 mg/dl) (23%, 25%, and 32%, respectively) (P = 0.0061 for trend). Table 3 shows ORs for the risk of 10-year incidence of LVH in subjects belonging to the intermediate and highest SUA tertile compared to the lowest tertile as reference. In unadjusted analysis, subjects in the intermediate and highest tertile exhibited a 11% and 62% higher risk of developing LVH than controls, respectively. After adjustment for age, gender, entry LVM index, serum creatinine, diabetes, cholesterol, 24-h SBP, and antihypertensive treatment ORs for incident LVH persisted significant only in the highest SUA tertile (OR = 1.966, 95% CI = 1.158-3.339, P = 0.0123).
Finally, in additional analysis, statistical significance was largely attenuated after correction for BMI. The full adjusted OR for the risk of LVH entailed to 1-unit increase in SUA was 1.117 (95% CI = 1.081-1.392, P = 0.046) and that associated with the highest SUA tertile was (OR = 1.243, 95% CI = 1.096-1.286, P = 0.049), respectively.
DISCUSSION
A growing body of evidence supports the concept that hyperuricemia is associated to increased risk of subclinical organ damage, cardiovascular morbidity, and mortality. 28 The role of hyperuricemia as an independent risk factor exerting direct adverse effects on cardiovascular structure or as an indirect marker of adverse prognostic value as often associated with established risk factors, remains debated.
Previous studies addressing the relationship between SUA and target organ damage were based on a cross-sectional design; in particular, no prospective data are available on SUA impact on long-term progression of subclinical cardiac damage, as assessed by echocardiography, in members of the general population free of subclinical cardiac abnormalities at baseline evaluation.
The results of our long-term longitudinal investigation on a urban community-based sample provide new findings on the association of SUA and incident LVH, as summarized here.
Incidence of LVH
A total of 258 new cases of LVH were observed over a 10-year period; thus, echocardiographic LV changes of adverse prognostic significance occurred in more than one quarter of subjects from our community sample with normal LV structure at the initial evaluation. Of note, the majority of new-onset LVH cases were observed in subjects in the 4 th and 5 th age decades, as the participants of the PAMELA study at entry aged on average 49 years.
Limited information is available about the time course of LV structural changes at the community level and about determinants of the progression from normal to subclinical cardiac disease. Data from The Coronary Artery Risk Development in Young Adults (CARDIA) study, reported a 20% incidence of LVH in subjects from a general population at the end of a 25-year follow-up period. 29 In the Framingham Offspring study up to 20% of the 2,874 participants with normal LV geometry at baseline (mean age 50 years, 59% women) progressed to concentric remodelling over a 4-year follow-up; less than 10% of cases, however, progressed to LVH. 30 At variance from the Framingham Offspring study, 30 our study based on a longer time of observation shows that a much larger fraction of a general population-based sample progressed to LVH.
Although a comprehensive discussion of factors predicting new-onset LVH in the community is beyond the aim of the present report, some aspects of this relevant issue deserve to be briefly commented. Data from Framingham study indicate that age, male sex, higher baseline levels of office BP and BMI are the most important factors associated with increased odds of developing abnormal LV geometry. 30 Recent data from our group focusing on longitudinal changes in LV geometric patterns and their correlates in the PAMELA population, in line with Framingham's investigators, showed that age, BMI, office BP, and initial LVM index were the main determinants of new-onset abnormal LV geometry. 31 Thus, demographic variables such as age and gender, as well as baseline BP and LVM indexed to body size, in particular to height 2.7 in order to minimize the effect of overweight/obesity, should be carefully considered in studies aimed to investigate the potential role of emerging new factors, including SUA, in predicting incident LVH.
SUA and new-onset LVH
The novel finding of the present analysis evaluating the factors associated to LVH incidence in a general population supports the role of SUA as an adverse factor affecting cardiac structure, independently of established cardiovascular risk factors, such as hypertension, metabolic syndrome, and renal dysfunction. In our series, indeed, increased SUA levels predicted incident LVH and the association persisted significant after adjustment of data for confounders, including age, gender, metabolic risk factors, entry LVM index, BP, and antihypertensive drugs. The predictive role of SUA was anything but marginal, as each 1 mg/dl SUA increase after adjustment was associated with a 26% increased risk of LVH. This unfavorable trend was even more evident when LVH incidence in the highest SUA tertile was compared to the lowest tertile, as subjects in the former group exhibited a 96% greater risk of developing LVH compared to their counterparts. It should be noted that the association between SUA and incident LVH was largely attenuated after adjustment for BMI. However, as in our analysis LVH was defined according to LVM normalized to allometric power of 2.7 (i.e., an indexation method that take into account the influence of overweight/obesity on LV structure), it is likely that correction for BMI may underestimate the strength of association between SUA and LVH.
To the best of our knowledge, no information is available from previous studies about the association between SUA and risk of new-onset echocardiographic LVH in representative population-based samples. Recently, the Brisighella Heart Study, 32 including 1,557 healthy subjects without LVH at initial examination, examined the independent predictive significance of SUA on the occurrence of electrocardiographic alterations during a 4-year follow-up. The authors demonstrated that SUA was a significant middle-term predictor of electrocardiographically diagnosed LVH, myocardial infarction, and arrhythmias.
Available evidence on the relationship between SUA and LVH remains exclusively based on findings provided by cross-sectional studies. In a rural Chinese cohort of 6,029 women (3508, 58% postmenopausal), prevalence of echocardiographic LVH showed a gradual increase across SUA quartiles in the entire study population (<4.0 mg/dl, 11.4%; 4 to <5 mg/dl, 14.9%; 5 to <6 mg/dl, 18.9%; ≥6 mg/dl, 27.4%). 33 Multivariate analysis revealed that hyperuricemia remained an independent risk factor for LVH in postmenopausal but not in premenopausal women. A retrospective study performed by Lyang et al. 34 in 577 elderly with permanent nonvalvular atrial fibrillation documented that SUA, age, male sex, the presence of coronary heart disease, and diuretic therapy were the main independent correlates of LVH. Of note, a gender-based subanalysis identified SUA as a significant risk factor associated with LVH only in men.
Numerous studies conducted in a setting at high prevalence of LVH, such as the hypertensive population, yielded conflicting results. In their pioneering investigation on 425 middle-aged, untreated patients with essential hypertension, Viazzi et al. 17 showed that each SD increase in SUA entailed a 75% higher risk of LVH (and a 2-times greater risk of carotid abnormalities) after adjustment for confounders. These results have been confirmed subsequently in some reports, [17] [18] [19] but not in other studies that failed to find an independent association between SUA and LVH. 20, 21 Discrepancies among studies may be related to differences in statistical power or in demographic and clinical characteristics of the subjects examined.
Experimental and clinical data suggesting a direct influence of SUA on cardiomyocyte growth and fibrosis merit to be mentioned. Three experimental studies reported that allopurinol was able to regress LVH in experimental models of cardiac disease. [35] [36] [37] Moreover, Losartan, an angiotensin receptor-1 antagonist with uricosuric properties, has been reported to reduce pressure overload LVH in mice independently of BP changes, an effect possibly related to the significant reduction in reactive oxygen species. 38 In humans, regression of LVH induced by allopurinol has been demonstrated in clinical trials carried out in chronic kidney disease, 39 ischemic heart disease 40 
Limitations of the study
First, our study does not clarify the mechanisms involved in the adverse effect of SUA on cardiac structure. Second, our analysis was restricted to LVH and did not examine new-onset systolic/diastolic LV dysfunction or LV concentric remodeling. Third, our results refer to a middle-aged population with low prevalence of diabetes and obesity, they should not be extended to other populations with different demographic and clinical features.
In conclusion, echocardiographic LVH is a strong, independent predictor of cardiovascular morbidity and mortality. Our study is the first to provide some evidence that SUA plays an independent role in the development of this harmful cardiac phenotype. In a practical perspective, lifestyle and pharmacologic interventions aimed to reduce SUA levels should be considered to prevent LVH development in the general population.
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